Company intelligence / Profile preview

ESGL Holdings

Ownership: Public · ESGL
Development stage: Commercial

Overview

As a blank check company/SPAC, ESGL does not have its own R&D programs or clinical pipeline. Its purpose is to identify and merge with/acquire an operating business in the biotech or pharmaceutical sector. All information about specific programs will depend on post-acquisition activities.

Industry: Investors

Financials

Market cap: $80.1M
Enterprise value: $86M

Beyond the preview

Go deeper on ESGL Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESGL Holdings.

Explore the full profile